3.03
+0.245(+8.81%)
Currency In USD
| Previous Close | 2.78 |
| Open | 2.77 |
| Day High | 3.08 |
| Day Low | 2.72 |
| 52-Week High | 4.03 |
| 52-Week Low | 1.05 |
| Volume | 1.41M |
| Average Volume | 1.25M |
| Market Cap | 327.74M |
| PE | -1.86 |
| EPS | -1.63 |
| Moving Average 50 Days | 2.25 |
| Moving Average 200 Days | 1.75 |
| Change | 0.25 |
If you invested $1000 in Aclaris Therapeutics, Inc. (ACRS) 10 years ago, it would be worth $143.16 as of December 04, 2025 at a share price of $3.025. Whereas If you bought $1000 worth of Aclaris Therapeutics, Inc. (ACRS) shares 5 years ago, it would be worth $808.82 as of December 04, 2025 at a share price of $3.025.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 25, 2025 1:00 PM GMT
WAYNE, Pa., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walke
Aclaris Therapeutics to Participate in Three November Healthcare Conferences
GlobeNewswire Inc.
Oct 29, 2025 11:30 AM GMT
WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company wi
Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025
GlobeNewswire Inc.
Sep 30, 2025 11:00 AM GMT
WAYNE, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company w